Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

YouTube Video Suggesting Livalo Is Safer Than Other Statins Is Dinged By US FDA

Executive Summary

Kowa Pharmaceuticals' patient testimonials implying switch from statins to Livalo will reduce drug side effects are misleading, untitled letter says.

You may also be interested in...



Metuchen Must Correct ED Drug Ads For Adult Sites After US FDA Warning Letter

Promotional campaign for Stendra (avanafil) included "adult sites" as well as the American College of Cardiology's patient-focused magazine; statements that FDA found problematic in the various ads include "get hard and stay hard" and calling the product a "next generation" PDE-5 inhibitor.

Eskata Video Ad Broadcast On The View Gets Rebuke From US FDA

Agency says superimposed text about risks and efficacy is overshadowed by "attention-grabbing before-and-after photographs" of patients treated with the seborrheic keratoses treatment.

Qsymia Webpage’s ‘3 Times Faster’ Weight-Loss Claims Draw US FDA Ire

Claims that Vivus' obesity drug helps patients lose weight faster than diet and exercise alone are false and misleading because the clinical studies were not designed to evaluate the rate of weight loss over time, Office of Prescription Drug Promotion says in untitled letter; Vivus says it is finalizing revisions to its promotions.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS140922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel